In the present study, we set out to address the question whether the combination of lymphodepleting chemotherapy of CTX at 30 mg/kg followed by Fludarabine at 30 mg/m2 and adoptive transfer of autologous PBMCs in association to a MART-1 peptide vaccination with or without the presence of the adjuvant IMP321 would elicit a more robust and long-lasting anti-tumor immunity that would finally improve patient outcome. This evidence concerns the gene MLANA and neoplasm.